SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (295)10/17/2005 6:27:25 PM
From: tuck  Read Replies (1) | Respond to of 447
 
All pretty low doses, too (the AMD dose is 3.47 mg). And at three years for the trial, we could see off-label use of Lucentis -- or even Avastin -- for this long before then, damnit.

I'd been looking for positives to this munch off EYET, but I'm having a hard time finding 'em.

Cheers, Tuck



To: Miljenko Zuanic who wrote (295)10/17/2005 7:29:49 PM
From: DewDiligence_on_SI  Respond to of 447
 
Doses range ratio of 1 : 100, in PIII???? Wow!

In the phase-3 AMD trials, the lowest of the three tested doses of Macugen worked better than the higher doses.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News